

18.04.2024

To, The Manager-Listing BSE Limited Mumbai

National Stock Exchange of India Ltd Mumbai.

Dear Sir,

## Sub : Disclosure of Deviation /variation in use of issue proceeds. Ref : Regulation 32 of SEBI(LODR) Regulations,2015.

With reference to the above cited subject and reference, we would like to clarify that the disclosure of deviation / variation in utilization of issue proceeds from the objects stated in the explanatory statement to the notice of the general meeting for the quarter ended 31.03.2024 is not applicable for our Company i.e Bal Pharma Limited, as the preferential issue proceeds has been fully utilised.

Request you to please take the same on record.

## For Bal Pharma Limited

CHITTANNAN DANCORKYCIII DD DAMODAR DD DAMODAR KOTIAN KOTIAN

Kotian Chittanand Darmodar Director